Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 15/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17637741 | 0.88 | HRH4 (0.69) | HRH4HRH3 | |
| SCHEMBL28791452 | 0.88 | HRH4 (0.69) | HRH4HRH3 | |
| SCHEMBL785843 | 0.84 | HRH4 (0.57) | HRH4HRH3 | |
| SCHEMBL30524183 | 0.82 | HRH3 (0.57) | HRH4HRH3 | |
| SCHEMBL13506774 | 0.82 | HRH3 (0.57) | HRH4HRH3 | |
| SCHEMBL1775060 | 0.80 | HRH4 (0.50) | HRH4HRH3 | |
| SCHEMBL20063949 | 0.79 | HRH4 (0.59) | HRH4HRH3HCRTR1HCRTR2 | |
| SCHEMBL17637738 | 0.77 | HRH4 (0.53) | HRH4HRH3GPBAR1 | |
| SCHEMBL24454273 | 0.77 | HRH4 (0.51) | HRH4HRH3HCRTR1HCRTR2 | |
| SCHEMBL1589764 | 0.76 | HRH4 (0.83) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018069863-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-19 | — | — | WO | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | HRH4 184/4885HRH3 187/4885HCRTR1 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.